Merck (NYSE: MRK) announced efficacy and safety data in previously untreated adults with HIV-1 infection for the company’s investigational once-daily ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE